Regulator flags gaps in Bharat Biotech's TB vaccine trial
Indian regulators have paused Phase-III trials for Bharat Biotech's tuberculosis vaccine due to identified data gaps and a serious adverse event. The committee requires further validation of immunogenicity data before the trial can proceed.
Why it matters
As India faces a high tuberculosis burden, the delay of a promising vaccine candidate impacts public health timelines and clinical development standards.
This is a Mint Premium article gifted to you. Subscribe to enjoy similar stories.
The report relies on official committee minutes and regulatory findings, maintaining a factual tone.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in